Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other ...
Concord Biotech reported revenue of 11.80 billion INR for fiscal year 2025, up 18.2% from fiscal year 2024, and net income of 3.72 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 2.47 billion INR, down 20.4% from a year before. India was its largest region in fiscal year 2025, with 55% of revenue. Its market capitalization was 141.69 billion INR as of October 12, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 12, 2026.
No profile data available.